Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism
|
|
- Jeffrey Charles
- 6 years ago
- Views:
Transcription
1 The Journal of International Medical Research 2011; 39: Total Parathyroidectomy with Forearm Autotransplantation as the Treatment of Choice for Secondary Hyperparathyroidism J NARANDA 1,2, R EKART 1,3 AND B PEČOVNIK-BALON 1,2 1 Faculty of Medicine, University of Maribor, Maribor, Slovenia; 2 Nephrology Department, and 3 Dialysis Department, University Clinical Centre Maribor, Maribor, Slovenia Chronic kidney disease mineral and bone disease (CKD MBD) is associated with uraemic bone disease, vascular calcification, reduced quality of life and reduced survival. This study evaluated the efficacy of parathyroidectomy (PTX) with autotransplantation in improving shortterm and long-term outcomes. Dialysis patients who underwent PTX showed significantly more favourable biochemical parameters after PTX. These changes were accompanied by a lower coronary artery calcification score, reduced thickness of the intimae media and comparable bone mineral density measures compared with control dialysis patients who did not undergo PTX. Despite the risk of a substantially lower intact parathyroid hormone level postoperatively that might lead to adynamic bone disease, none of the patients reported clinical signs of this disease, such as bone pain or fractures. In conclusion, PTX with autotransplantation led to improvement of CKD MBD so may be considered in patients with secondary hyperparathyroidism that is resistant to treatment with vitamin D analogues and calcimimetics. KEY WORDS: CHRONIC KIDNEY DISEASE; HYPERPARATHYROIDISM; MINERAL AND BONE DISEASE; CALCIFICATION; PARATHYROIDECTOMY; MINERAL METABOLISM; BONE MINERAL DENSITY Introduction Secondary hyperparathyroidism (SHPT) is a common complication among patients with chronic kidney disease (CKD) and represents part of a broad spectrum of mineral metabolism disorders that occur in this clinical setting. 1 3 Alterations in the control mechanisms for calcium and phosphorus homeostasis, which occur early in the course of CKD and progress as kidney function decreases, along with diminished value of active vitamin D, lead to an increase of serum intact parathyroid hormone (ipth) and results in SHPT. 4 The term CKD mineral and bone disease (CKD MBD) is now used to describe the systemic manifestations of CKD that include abnormalities in calcium, phosphorus, ipth and vitamin D metabolism, abnormalities in bone turnover (mineralization, volume, growth), and vascular calcifications and deposits of calcium in soft tissues
2 Bone abnormalities due to CKD include the effects of high levels of ipth on bone, which results in the high-turnover bone disease, osteitis fibrosa. 1 In contrast, adynamic bone, characterized by extremely low bone turnover, may also occur in the setting of CKD or after parathyroidectomy (PTX). 8 This wide spectrum of skeletal abnormality can give rise to a variety of mixed patterns. High-turnover bone disease is the result of SHPT development. It has been shown that hyperplasia of the parathyroid glands and high levels of ipth occur early in the course of CKD and lead to over-activity of the parathyroid gland. 9 The factors that influence parathyroid gland hyperplasia include the retention of phosphorus, decreased levels of calcitriol, intrinsic alterations within the parathyroid glands, skeletal resistance to ipth and hypocalcaemia. 10 Research indicates that 5 25% of patients with CKD develop severe forms of SHPT while, in another 75%, nodular dysplasia of the parathyroid gland can be found histologically. 11 The majority of patients can, however, be successfully treated conservatively by controlling the serum level of phosphorus with dietary intake restrictions and phosphorus binders to reduce gastrointestinal tract absorption. 12 Additionally, the level of calcium can be controlled by monitoring calcium levels in the daily diet relative to calcium levels in serum, by adjusting the level of calcium in dialysis fluid, and with the use of vitamin D analogues In spite of advances in medical therapy, some patients with CKD become resistant to drug treatment and, therefore, still have marked elevations in serum ipth. This disorder is called tertiary hyperparathyroidism (THPT). It characteristically presents with hyper - calcaemia and refractory hyperpara - thyroidism due to hyperfunctional parathyroid tissue that does not respond appropriately to physiological regulation or to medical therapy. 19 The most probable causes of THPT are thought to be delayed and/or inadequate therapy, persistent hyperphosphataemia leading to irreversible parathyroid gland hyperplasia and autonomous behaviour of the parathyroid gland. 20 These patients have a greater risk of developing CKD MBD and require aggressive operative treatment, i.e. PTX, in order to prevent long-term complications The parathyroid gland can be removed partially (subtotal PTX) or totally (total PTX) with or without autotransplantation (AT). 24 In most cases, PTX results in a dramatic reduction in the serum ipth level, an improvement of SHPT and a decrease in the risk of cardiovascular diseases and bone fractures. 11,25 Substantially low ipth levels that are usually reported postoperatively may predispose a patient to adynamic bone disease (ABD) and can also lower the patient s quality of life due to the clinical symptoms of fractures, bone pain and vascular calcifications. 26 The aim of the present study was to evaluate the efficacy of PTX with AT, which is one of the surgical treatment options for patients that develop severe forms of SHPT due to CKD and who do not respond to the recommended drug therapy. Patients and methods STUDY POPULATION AND DESIGN This study was carried out at the University Clinical Centre, Maribor, Slovenia, between 2003 and All dialysis patients who underwent total PTX with AT of one parathyroid gland in the forearm due to SHPT because of CKD were enrolled into the study. Indications for PTX were very high levels of ipth (> 900 pg/ml) that could not be normalized with the drug treatment available at the time. Dialysis patients who 979
3 did not undergo PTX with AT, matched for age, gender, duration of dialysis treatment and mean ipth value, were selected to form a control group. This study was a retrospective observational study so ethical approval was not required. All patients enrolled into the study were informed about the aim of the study and their verbal consent was obtained. STUDY TREATMENT AND MONITORING Dialysis patients who underwent PTX with AT were treated three times per week for 4 6 h on a Gambro AK 200 dialysis apparatus (Rhein Medical Solutions, Duesseldorf, Germany). The level of calcium in dialysis fluid was kept at mmol/l based on the calcium and phosphorus electrolyte levels in serum. Serum calcium, phosphorus, and alkaline phosphatase levels were monitored once a month for 6 months preoperatively and ipth was measured once every 4 months. After PTX, all biochemical parameters were monitored once a month and ipth once per 4 months. Measurement taken immediately after PTX was a single measurement and was recorded as the measurement at 1 month. Other measurements were recorded as the mean values for 12, 24 and 36 months; for example, the measurement recorded for 12 months was the mean value of all measurement taken in the first year after PTX, the measurement recorded for 24 months was the mean value of all measurement taken in the second year after PTX, and so on. Levels of ipth were measured with the Elecsys immunoassay kit (Roche Diagnostics, Mannheim, Germany) and the other biochemical parameters were measured using standard biochemical methods. Patients were treated with phosphorus binders (calcium carbonate, sevelamer) and calcitriol. POSTOPERATIVE EVALUATIONS From the dialysis patients who underwent PTX with AT, a subgroup with full data availability was selected as a test group to be compared with a control group of comparable age, gender and duration of dialysis. The coronary artery calcification score (CACS), thickness of the intima media (TIM) and bone mineral density (BMD) were measured in both the test and control groups of dialysis patients. CACS was estimated using the scale of Agatson et al. 27 following multislice spiral computed tomography (CT) with a Toshiba Aquilion 64 scanner (Toshiba Medical Systems Corp., Otawara, Japan). TIM was obtained by ultrasound using a Philips ATL HDI 3000 ultrasound machine (Philips Healthcare, Best, The Netherlands). BMD (absolute value [g/m 2 ], percentage value and T-score) was measured using a Hologic QDR 2000 Plus densitometer (Braintec, Ljubljana, Slovenia). Patients in both groups were also evaluated for clinical signs of bone fractures, bone pain and pruritus. STATISTICAL ANALYSES The mean ± SD of the data were calculated and statistical analyses were carried out using the SPSS statistical package, version 12.0 (SPSS Inc., Chicago, IL, USA) for Windows. Data were compared by t-test for paired and independent samples. A P-value < 0.05 was considered to be statistically significant. Results Of the 26 dialysis patients who developed SHPT because of CKD and underwent PTX with AT, only 17 (12 females, five males) could be followed postoperatively: three from the time of the operation until death and the remaining 14 for a mean ± SD of 2.5 ± 1.0 years postoperatively. Nine patients were excluded: five of them underwent kidney 980
4 transplantation, three died soon after the operation and one changed health institutions. The 17 patients included in the analysis had the following diagnoses: four had autosomal dominant polycystic kidney disease, three had chronic glomerulonephritis, two had diabetic nephropathy, two had chronic pyelonephritis, one had cysplatin nephropathy, one had Balkan nephropathy, one had analgesic nephropathy, one had reflux nephropathy and two had unknown diagnoses. The characteristics of the 26 dialysis patients who underwent PTX with AT and the group of 17 patients that were followed postoperatively are shown in Table 1. Among the 17 patients who underwent PTX with AT, only the nine patients who had full data availability (CACS, TIM and BMD) were chosen as the test group; the remaining eight patients refused to undergo diagnostic procedures. The test group was compared with nine dialysis patients who had not undergone PTX with AT (control group), matched to the test group for age, gender distribution, and duration of dialysis treatment in order to generate two comparable groups (Table 2). Table 3 presents the mean preoperative (6 months) and postoperative levels for the biochemical parameters for the 17 patients who underwent PTX with AT. Before the operation, none of the patients was hypercalcaemic, two (12%) had hyperphosphataemia and seven (41%) had overly high values for the calcium phosphorus product (> 4.4 mmol 2 /l 2 ). Postoperatively, only two (12%) patients achieved a mean level of serum ipth that was within the normal range; all patients had normal values for the calcium phosphorus product. Table 4 presents the mean postoperative levels of calcium, phosphorus, ipth and alkaline phosphatase at different time- TABLE 1: Baseline characteristics of dialysis patients who underwent parathyroidectomy (PTX) with autotransplantation (AT) and the group of patients followed postoperatively Gender Treatment Dialysis duration Duration after Group Age (years) (males/females; n) (n) (months) PTX (months) Total treated with PTX with AT (n = 26) 51.1 ± /17 HD = 22 PD = ± 58.9 Patients treated with PTX with AT and followed 55.3 ± /12 HD = 14 postoperatively (n = 17) PD = ± ± 12.0 Data presented as mean ± SD or number of patients (n). HD, haemodialysis; PD, peritoneal dialysis. 981
5 TABLE 2: Baseline characteristics of selected dialysis patients who underwent parathyroidectomy (PTX) with autotransplantation (AT) compared with the matched control dialysis patients (control) who did not undergo PTX with AT PTX with AT Control group Statistical Characteristics/parameters (n = 9) (n = 9) significance a Age, years 57 ± ± 13 NS Gender, males/females 3/6 4/5 Dialysis duration, months Overall 126 ± ± 64 NS Before PTX 82 ± 56 After PTX 43 ± 15 Data presented as mean ± SD or number of patients (n). a Independent-samples t-test; NS, not statistically significant (P > 0.05). TABLE 3: Biochemical analyses in the dialysis patients before and after parathyroidectomy with autotransplantation (n = 17) Biochemical parameter Preoperative Postoperative Normal range Intact parathyroid hormone, pg/ml 1467 ± ± 50* Calcium, mmol/l 2.37 ± ± 0.17* Phosphorus, mmol/l 1.80 ± ± 0.34* Alkaline phosphatase, µkat/l 2.52 ± ± 0.58* Calcium phosphorus product, mmol 2 /l ± ± 0.7* < 4.4 Data presented as mean ± SD of all preoperative (6 months) and postoperative measurements (mean ± SD time period of postoperative measurements was 2.5 ± 1.0 years). *P < 0.05 versus preoperative value (paired-samples t-test). TABLE 4: Biochemical analyses in the dialysis patients at 1, 12, 24 and 36 months after parathyroidectomy with autotransplantation 1 month 12 months 24 months 36 months Normal Biochemical parameter (n = 17) (n = 14) (n = 14) (n = 9) range Intact parathyroid 44 ± 62* 51 ± 60* 51 ± 49* 63 ± 50* hormone, pg/ml Calcium, mmol/l 2.22 ± ± ± 0.19* 2.08 ± Phosphorus, mmol/l 1.09 ± 0.49* 1.53 ± ± 0.38* 1.46 ± Calcium phosphorus 2.3 ± 0.8* 3.5 ± ± 0.9* 3.1 ± 1.2 < 4.4 product, mmol 2 /l 2 Alkaline phosphatase, µkat/l 1.51 ± ± 0.65* 1.31 ± 0.55* 1.57 ± Data presented as mean ± SD. All parameters were monitored once a month, except intact parathyroid hormone which was monitored once every 4 months. The measurement at 1 month is a single measurement taken immediately after parathyroidectomy. The 12 months measurement is the mean of all measurements taken in the first year after parathyroidectomy, the 24 months measurement is the mean of all second year measurements, and so on. *P < 0.05 versus preoperative value (paired-samples t-test). 982
6 TABLE 5: Biochemical analyses in the selected dialysis patients who underwent parathyroidectomy (PTX) with autotransplantation (AT) compared with the matched control dialysis patients (control) who did not undergo PTX with AT Biochemical parameter PTX with AT (n = 9) Control group (n = 9) Intact parathyroid hormone, pg/ml a Overall b 1147 ± 182* 892 ± 323 Before PTX 1484 ± 231 After PTX 42 ± 49 CACS a 1056 ± ± 2350 Intima media thickness, mm a 0.81 ± ± 0.78 Bone mineral density a Absolute value, g/m ± ± 0.55 Percentage, % c 96.4 ± ± 3.8 T-score d 1.41 ± ± 0.36 Clinical data, n Fractures 0 1 Pain 0 5 Pruritis 0 3 Data presented as mean ± SD or number of patients (n). a Overall intact parathyroid hormone, CACS, intima media thickness and bone mineral density measurements represent the mean ± SD of values taken for the following periods: PTX with AT group, 126 ± 65 months after the beginning of dialysis (or 82 ± 56 months after PTX); control group 103 ± 64 months after the beginning of dialysis. b Mean of before and after PTX. c Calculated as a percentage of the bone mineral density of young healthy adults. d Deviation from the bone mineral density of young healthy adults, recalculated as a standard deviation. *P < 0.05 versus control group (paired samples t-test). CACS, coronary artery calcification score. points after PTX. There was a gradual increase in ipth over time. Table 5 presents the ipth, CACS, TIM, BMD, bone fracture, bone pain and pruritus data for the test and matched control groups. None of the patients who underwent PTX with AT showed any clinical signs of fractures, bone pain or pruritus, whereas in patients who had not undergone PTX with AT, there was one fracture, five had bone pain and three had pruritis at follow-up. Discussion In the majority of CKD patients CKD MBD is present and is associated with disturbance of calcium and phosphorus homeostasis and altered vitamin D metabolism. 5 Excess levels of ipth, phosphorus and calcium are linked to parathyroid gland hyperplasia, renal bone disease, vascular calcifications, a lower quality of life and higher mortality Treatment of CKD MBD is stepwise, multidimensional, and must be initiated at an early stage in order to avoid complications and reduce the likelihood of the case becoming difficult to treat. Restriction of dietary phosphorus intake is introduced but phosphorus binders and vitamin D are also usually subsequently required. 20 Vitamin D analogues 31 and calcimimetics 32 have demonstrated efficacy in the prevention of CKD MBD. Unfortunately, during the study period ( ), neither vitamin D analogues nor calcimimetics were available at the University Clinical Centre Maribor. As a 983
7 result, many patients developed substantially high levels (> 300 pg/ml) of ipth and required PTX. 9 Paricalcitol (vitamin D analogue) and/or cinacalcet (calcimimetic) have been used at the University Clinical Centre Maribor since 2007 in patients developing high ipth levels despite dietary phosphorus restriction and treatment with phosphorus binders. In some patients, the effort to correct hyperphosphataemia with calcium-based phosphorus binders results in hypercalcaemia, especially when calcitriol is coadministered to suppress ipth secretion. 33 In the course of SHPT, nodular hyperplasia of the parathyroid gland develops with decreased calciumsensing receptors to regulate ipth secretion. 34 Altered receptor numbers make the parathyroid gland less responsive to medical treatment, cause skeletal resistance to ipth and renal bone disease. 20 The medical treatment of patients in the present study had been previously unsuccessful; all 17 patients had developed resistant SHPT (ipth > 900 pg/ml) with high levels of calcium and phosphorus. Seven patients (41%) had a calcium phosphorus value > 4.4 mmol 2 /l 2. It is known that hypercalcaemia and higher values of calcium phosphorus lead to vascular calcification and an increased risk for cardiovascular disease. 35 Thus, treatment with calcium and vitamin D had to be discontinued and PTX with AT was performed. The main finding of the present study was the correction of SHPT; all of the patients demonstrated significantly lower serum levels of ipth, calcium, phosphorus and alkaline phosphatase after treatment with PTX. The postoperative results were comparable with the literature reporting satisfactory biochemical and clinical results after PTX therapy which, in some cases, was achieved in > 95% of patients. 39 In spite of good short-term clinical results, there appears to be an increased risk of reaching overly low ipth values after PTX, which predisposes the patient to ABD, increases the risk of fractures and lowers the patient s quality of life. 40 Although only two (13%) patients in the present study reached the recommended Kidney Disease Improving Global Outcomes (KDIGO) ipth serum value ( pg/ml) postoperatively, 5 no clinical signs of fractures, bone pain or pruritus before or after PTX were observed. In contrast, these clinical signs were observed in the control group (one patient with fracture, five with bone pain and three with pruritus). Postoperative data showed transitory favourable bone metabolism, since the alkaline phosphatase level was significantly lower at 12 and 24 months after PTX. Furthermore, postoperative BMD parameters indicated satisfactory bone structure in patients who underwent PTX. 41,42 To evaluate the success of PTX with AT in lowering the long-term risk for cardiovascular disease and death, CACS and TIM were measured in the test and control groups. Lower mean values of CACS and TIM in patients who underwent PTX indicated that PTX was successful, despite the differences between the two groups only being numerical and not statistically significant. Other studies have also shown improved survival and fewer complications among patients who underwent PTX. 37,38 Despite a previous report of excellent shortterm clinical results and long-term normalization of ipth in 40% of patients after PTX, 39 overly low values of ipth are more usually reported. 40 Only two patients in the present study had ipth levels within the normal range; this occurred at a mean ± SD of 2.5 ± 1.0 years after PTX. Similarly, at 5 years after PTX, the main clinical finding reported in the literature is 984
8 hypoparathyroidism. 38 These patients have a long-term risk of developing ABD. By measuring the biochemical parameters at different time-points after PTX, it was demonstrated that the ipth level gradually increased but did not reach the minimal desired level. Although levels of calcium, phosphorus and alkaline phosphatase were improved after PTX, patients were still required to take calcium and vitamin D supplements. In conclusion, the present study demonstrated that PTX with AT is an efficient short-term treatment option for severe SHPT. Nevertheless, PTX with AT does not seem to be the optimum therapeutic option for patients with severe SHPT because it does not target the recommended National Kidney Federation Kidney Disease Outcomes Quality Initiative nor the KDIGO values for ipth. 5,40,43 The potential risk of an overly low ipth, which can lead to ABD, appears to be counter-balanced by the favourable effect of PTX on vascular calcification and improved long-term survival. New treatments for SHPT include vitamin D analogues and calcimimetics. Modulating the calcium-sensing receptor on the parathyroid gland, thereby lowering ipth secretion, improves bone remodelling and prevents parathyroid hyperplasia. 35 Since beginning use of these agents at the University Clinical Centre Maribor, there has been no need for PTX with AT. In patients who still require PTX because of severe SHPT that is resistant to drug treatment, histological assessment of the removed parathyroid gland should be performed and only the required amount of the active gland should be re-implanted. Some authors have already described satisfactory results with this technique. 35,44,45 Conflicts of interest The authors had no conflicts of interest to declare in relation to this article. Received for publication 17 January 2011 Accepted subject to revision 3 February 2011 Revised accepted 22 April 2011 Copyright 2011 Field House Publishing LLP References 1 Moe S, Drüeke T, Cunningham J, et al: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: Felsenfeld AJ, Llach F: Parathyroid gland function in chronic renal failure. Kidney Int 1993; 43: Hernández A, Concepción MT, Rodríguez M, et al: High phosphorus diet increases prepropth mrna independent of calcium and calcitriol in normal rats. Kidney Int 1996; 50: Nichols P, Owen JP, Ellis HA, et al: Parathyroidectomy in chronic renal failure: a nine-year follow-up study. Q J Med 1990; 77: Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD MBD). Kid Int 2009; 76(suppl 113): S1 S Guérin AP, London GM, Marchais SJ, et al: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2001; 15: Safar ME, Blacher J, Pannier B, et al: Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: Andress DL: Adynamic bone in patients with chronic kidney disease. Kidney Int 2008; 73: Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996; 11(suppl 3): Martin KJ, González EA: Metabolic bone disease and chronic kidney disease. J Am Soc Nephrol 2007; 18: Neyer U, Hoerandner H, Haid A, et al: Total parathyroidectomy with autotransplantation in renal hyperparathyroidism: low recurrence after intra-operative tissue selection. Nephrol Dial Transplant 2002; 17: Coladonato JA: Control of hyperphosphatemia 985
9 among patients with ESRD. J Am Soc Nephrol 2005; 16(suppl 2): S107 S Quarles LD, Davidai GA, Schwab SJ, et al: Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34: Mundy GR, Guise TA: Hormonal control of calcium homeostasis. Clin Chem 1999; 45: Shevde NK, Plum LA, Clagett-Dame M, et al: A potent analog of 1α,25-dihydroxyvitamin D 3 selectively induces bone formation. Proc Natl Acad Sci U S A 2002; 99: Goodman WG: Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003; 18(suppl 3): iii2 iii8. 17 Malluche HH, Mawad H: Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions. Nephrol Dial Transplant 2002; 17: Drueke T, Martin D, Rodriguez M: Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007; 22: Lewin E, Huan J, Olgaard K: Parathyroid growth and suppression in renal failure. Semin Dial 2006; 19: Berkoben M, Cronin RE, Quarles LD: Indications for parathyroidectomy in end-stage renal disease. UpToDate (available at: 7E150). 21 Ritter CS, Martin DR, Lu Y, et al: Reversal of secondary hyperparathyroidism by phosphate restriction restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 2002; 17: Quarles LD, Davidai GA, Schwab SJ, et al: Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34: Fabretti F, Calabrese V, Fornasari V, et al: Subtotal parathyroidectomy for secondary hyperparathyroidism in chronic renal failure. J Laryngol Otol 1991; 105: Llach F: Parathyroidectomy in chronic renal failure: indications, surgical approach and the use of calcitriol. Kidney Int Suppl 1990; 29: S62 S Abdelhadi M, Nordenström J: Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998; 83: Taal MW, Masud T, Green D, et al: Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999; 14: Agatston AS, Janowitz WR, Hildner FJ, et al: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: Malberti F, Farina M, Imbasciati E: The PTH calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999; 14: Rudser KD, de Boer IH, Dooley A, et al: Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol 2007; 18: Bover J, Rodriguez M, Trinidad P, et al: Factors in the development of secondary hyperparathyroidism during graded renal failure in the rat. Kidney Int 1994; 45: Cozzolino M, Brandenburg V: Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the U. Clin Nephrol 2009; 71: Goodman WG, Frazao JM, Goodkin DA, et al: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: Goodman WG: Recent developments in the management of secondary hyperpara - thyroidism. Kidney Int 2001; 59: Chen RA, Goodman WG: Role of the calciumsensing receptor in parathyroid gland physiology. Am J Physiol Renal Physiol 2004; 286: F1005 F Block GA, Hulbert-Shearon TE, Levin NW, et al: Association of serum phosphorus and calcium phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: Kaye M, Rosenthall L, Hill RO, et al: Long-term outcome following total parathyroidectomy in patients with end-stage renal disease. Clin Nephrol 1993; 39: Rashed A, Fahmi M, ElSayed M, et al: Effectiveness of surgical parathyroidectomy for secondary hyperparathyroidism in renal dialysis patients in Qatar. Transplant Proc 2004; 36: Gagné ER, Ureña P, Leite-Silva S, et al: Shortand long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992; 3: Kestenbaum B, Andress DL, Schwartz SM, et al: Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004; 66: Mazzaferro S, Pasquali M, Farcomeni A, et al: Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant 2008; 23: Torres A, Lorenzo V, Hernández D, et al: Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47:
10 42 Qi Q, Monier-Faugere MC, Geng Z, et al: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995; 26: National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 suppl 3): S1 S Coen G, Calabria S, Bellinghieri G, et al: Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia. Nephron 2001; 88: Sato S, Ohta M, Kawaguchi Y, et al: Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner Electrolyte Metab 1995; 21: Author s address for correspondence Dr Jakob Naranda Faculty of Medicine, University of Maribor, Slomškov trg 15, SI-2000 Maribor, Slovenia. mf@uni-mb.si 987
Therapeutic golas in the treatment of CKD-MBD
Therapeutic golas in the treatment of CKD-MBD Hemodialysis clinic Clinical University Center Sarajevo Bantao, 04-08.10.2017, Sarajevo Abbvie Satellite symposium 06.10.2017 Chronic Kidney Disease Mineral
More informationDo We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital
Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker
More informationHYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY
UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationNew biological targets for CKD- MBD: From the KDOQI to the
New biological targets for CKD- MBD: From the KDOQI to the KDIGO Guillaume JEAN, MD. Centre de Rein Artificiel, 42 avenue du 8 mai 1945, Tassin la Demi-Lune, France. E-mail : guillaume-jean-crat@wanadoo.fr
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationRenal Association Clinical Practice Guideline in Mineral and Bone Disorders in CKD
Nephron Clin Pract 2011;118(suppl 1):c145 c152 DOI: 10.1159/000328066 Received: May 24, 2010 Accepted: December 6, 2010 Published online: May 6, 2011 Renal Association Clinical Practice Guideline in Mineral
More informationTreatment Options for Chronic Kidney
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia The 17th Budapest Nephrology School, August 29, 2010 Session Objectives Definition
More informationCinacalcet treatment in advanced CKD - is it justified?
Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to
More informationCKD-MBD CKD mineral bone disorder
CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature
More informationThe impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure
Nephrol Dial Transplant (2002) 17: 340 345 The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure Naseem Amin Genzyme Corporation, Cambridge, MA,
More informationGuidelines and new evidence on CKD - MBD treatment
Guidelines and new evidence on CKD - MBD treatment Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia ERA-EDTA CME course IV Congress of Nephrology of B&H, April 25, 2015, Sarajevo,
More informationDifferent effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism
Nephrol Dial Transplant (996) : 8-87 Original Article Nephrology Dialysis Transplantation Different effects of calcitriol and parathytoidectomy on the PTH-calcium curve in dialysis patients with severe
More informationManagement of CKD. Goce Spasovski, R. Macedonia
Management of CKD complications Introduction Bone disease to Renagel Goce Spasovski, R. Macedonia Istanbul, June 4, 2011 Session Objectives - Mineral and Bone Disorders (MBD) Bone disease a part of CKD
More information( ) , (Donabedian, 1980) We would not choose any treatment with poor outcomes
..., 2013 Amgen. 1 ? ( ), (Donabedian, 1980) We would not choose any treatment with poor outcomes 1. :, 2. ( ): 3. :.,,, 4. :, [Biomarkers Definitions Working Group, 2001]., (William M. Bennet, Nefrol
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationThe role of calcimimetics in chronic kidney disease
http://www.kidney-international.org & 2006 International Society of Nephrology The role of calcimimetics in chronic kidney disease A Gal-Moscovici 1,2 and SM Sprague 1 1 Division of Nephrology and Hypertension,
More informationSensipar. Sensipar (cinacalcet) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)
More informationThe Parsabiv Beginner s Book
The Parsabiv Beginner s Book A quick guide to help you learn about your treatment with Parsabiv and what to expect Indication Parsabiv (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism
More informationOPEN. Masahiro Yoshikawa 1,2, Osamu Takase 1,2, Taro Tsujimura
www.nature.com/scientificreports Received: 26 September 2017 Accepted: 19 March 2018 Published: xx xx xxxx OPEN Long-term effects of low calcium dialysates on the serum calcium levels during maintenance
More informationCalcium x phosphate product
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Calcium x phosphate product GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL
More informationTreatment Options for Chronic Kidney. Goce Spasovski, R. Macedonia
Treatment Options for Chronic Kidney Disease: Metabolic Introduction Bone Disease to Renagel Goce Spasovski, R. Macedonia Budapest, August 29, 2011 Session Objectives Definition of the problem of CKD-MBD
More informationRamzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016
Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationRenal Bone Disease: 25-year Experience From a Single Center
Original Article Renal Bone Disease: 25-year Experience From a Single Center Kwok-Hong Chu, 1 Au Cheuk, 1 William Lee, 1 Ka-Fai Yim, 1 Hon-Lok Tang, 1 Ka-Shun Fung, 1 Kam-Cheong Lee, 2 Kwok-Lung Tong,
More information... . : ... PTH.
IRMA Email msarookhani@qumsacir * CRD GFR D [1,25OH 2 D 3 ] SHPT GFR» «KDOQI SHPT Ca * P P P Selectra Overt HPT = = Ca * P P > GM II DSL i IRMA ± ± ± Ca * P % % % % % % % % % % % % % % % % pgml = = > ±
More informationEffects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2
Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and
More informationEffect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
Nephrol Dial Transplant (2003) 18 [Suppl 3]: iii42 iii46 DOI: 10.1093/ndt/gfg1011 Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients Kazuhiro Shiizaki
More informationSecondary hyperparathyroidism an Update on Pathophysiology and Treatment
Secondary hyperparathyroidism an Update on Pathophysiology and Treatment Klaus Olgaard Copenhagen Budapest Nephrology School August 2007 HPT IN CRF Renal mass Ca 2+ 1,25(OH) 2 D 3 CaR Hyperparathyroidism
More informationRisk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism
Ho et al. BMC Nephrology (2017) 18:12 DOI 10.1186/s12882-016-0421-5 RESEARCH ARTICLE Open Access Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients
More informationAbnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism
Nephrol Dial Transplant (1996) 11: 1292-1298 Original Article Mephrology Dialysis Transplantation Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism. Berdud, A.
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Prevalence and Pattern of Mineral Bone Disorder in Chronic Kidney Disease Patients Using Serum
More informationUltrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism
Ultrasound examination in diagnosis of morphological variants of parathyroid hyperplasia in patients with secondary hyperparathyroidism Poster No.: C-0304 Congress: ECR 2015 Type: Authors: Keywords: DOI:
More informationIncorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience
Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among
More informationNuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416)
Nuove terapie in ambito Nefrologico: Etelcalcetide (AMG-416) Antonio Bellasi, MD, PhD U.O.C. Nefrologia & Dialisi ASST-Lariana, Ospedale S. Anna, Como, Italy Improvement of mineral and bone metabolism
More informationCLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015)
CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD) Final Version (01/03/2015) Dr Simon Steddon, Consultant Nephrologist, Guy s and St Thomas NHS Foundation Trust, London Dr Edward Sharples,
More information2017 KDIGO Guidelines Update
2017 KDIGO Guidelines Update Clinic for Hemodialysis Clinical Center University of Sarajevo 13 th Congress of the Balkan cities Association of Nephrology, Dialysis, and Artificial Organs Transplantation
More informationIntroduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a
Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença
More informationRenal Osteodystrophy. Chapter 6. I. Introduction. Classification of Bone Disease. Eric W. Young
Chapter 6 Renal Osteodystrophy Eric W. Young I. Introduction Renal osteodystrophy refers to bone disease that occurs in patients with kidney disease. Bone disease occurs across the full spectrum of kidney
More informationHyperphosphatemia is associated with a
TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular
More informationCase Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism after Subtotal Parathyroidectomy
SAGE-Hindawi Access to Research International Nephrology Volume 211, Article ID 246734, 6 pages doi:1.461/211/246734 Case Report Use of Percutaneous Ethanol Injection Therapy for Recurrent Secondary Hyperparathyroidism
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationAttivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi
Attivazione selettiva dei VDR nella CKD-MBD: dalla conservativa alla dialisi Mario Cozzolino, MD, PhD, FERA Dipartimento di Scienze della Salute Università di Milano UO Nefrologia e Dialisi Laboratorio
More informationMarie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche
Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude
More informationDrugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia
NSW Therapeutic Advisory Group Level 5, 376 Victoria Street PO Box 766 Darlinghurst NSW 2010 Phone: 61 2 8382 2852 Fax: 61 2 8382 3529 Email: nswtag@stvincents.com.au www.nswtag.org.au Drugs for the treatment
More informationAmol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through
Research Article ISSN: 0974-6943 Amol K Choulwar et al. / Journal of Pharmacy Research 2012,5(1), Available online through www.jpronline.info Comparison of efficacy and safety of Cinacalcet versus Calcitriol
More informationPREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL
PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide
More informationImproved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis
ORIGINAL ARTICLE Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis Masaki Ohya 1, Haruhisa Otani 2,KeigoKimura 3, Yasushi Saika 4, Ryoichi Fujii 4, Susumu
More informationSensipar (cinacalcet)
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPRIMARY HYPERPARATHYROIDISM
PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and
More informationShould cinacalcet be used in patients who are not on dialysis?
Should cinacalcet be used in patients who are not on dialysis? Jorge B Cannata-Andía and José Luis Fernández-Martín Affiliations: Bone and Mineral Research Unit. Hospital Universitario Central de Asturias.
More informationK/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients
http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationClinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet:
Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: Results of a prospective randomized controlled study Forni Valentina¹, Pruijm Menno¹,
More information02/27/2018. Objectives. To Replace or Not to Replace: Nutritional Vitamin D in Dialysis.
To Replace or Not to Replace: Nutritional Vitamin D in Dialysis. Michael Shoemaker-Moyle, M.D. Assistant Professor of Clinical Medicine Objectives Review Vitamin D Physiology Review Current Replacement
More informationContents. Authors Name: Christopher Wong: Consultant Nephrologist Anne Waddington: Renal Pharmacist Eimear Fegan : Renal Dietitian
Cheshire and Merseyside Renal Units Guidelines on the Management of Chronic Kidney Disease - Mineral Bone Disorder (adapted from Greater Manchester) Authors Name: Christopher Wong: Consultant Nephrologist
More informationA calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication
Kidney International, Vol. 53 (1998), pp. 223 227 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure Rapid Communication JOHN E. ANTONSEN, DONALD
More informationOriginal Article. Introduction
Nephrol Dial Transplant (2006) 21: 1663 1668 doi:10.1093/ndt/gfl006 Advance Access publication 6 February 2006 Original Article Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism
More informationSetting the standard
SCLEROSTIN in NEPHROLOGY MOST REFERENCED OPTIMIZED FOR CLINICAL SAMPLES Setting the standard for clinical research. SCLEROSTIN A BONE-RELATED PROTEIN URINE PROTOCOL AVAILABLE Sclerostin ELISA - Assay Characteristics
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationThe Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD
The Calcium Conundrum: When, What and How to Give Calcium in Pediatric CKD/ESRD Jess Tower MS RD LD 3/18/19 Children s Mercy Hospital jdtower@cmh.edu 816 460 1067 Disclosures Nothing to disclose 1 How
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More informationAchievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study
Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study Fernstrom, Anders; Giaever, Jan; Granroth, Barbara; Hylander,
More informationBsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients
Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco
More informationTitle:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Author's response to reviews Title:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism Authors: Li Fang (fangli@njmu.edu.cn)
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Effect on mortality of elective parathyroid surgery in one hundred and three patients with chronic kidney disease : our experience. White Rose Research Online URL for this
More informationEfficacy of intraoperative parathyroid hormone monitoring to predict success of parathyroidectomy for secondary hyperparathyroidism
J Korean Surg Soc 2012;83:1-6 http://dx.doi.org/10.4174/jkss.2012.83.1.1 ORIGINAL ARTICLE JKSS Journal of the Korean Surgical Society pissn 2233-7903 ㆍ eissn 2093-0488 Efficacy of intraoperative parathyroid
More informationLevel 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor
chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for
More informationGlycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy
Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPhosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis
IAMHD HOME HEMODIALYSIS CLINICAL PRACTICE STANDARDS AND PROCEDURES Phosphate Management Guideline for Patients Receiving Extended Duration Hemodialysis PRINTED copies of Clinical Practice Standards and
More informationORIGINAL ARTICLE. parathyroid graft function after presternal
ORIGINAL ARTICLE Parathyroid Graft Function After Presternal Subcutaneous Autotransplantation for Renal Hyperparathyroidism Miguel Echenique-Elizondo, MD, PhD; Francisco Javier Díaz-Aguirregoitia, MD,
More informationMeasurement of vascular calcification using CT fistulograms
Nephrol Dial Transplant (2007) 22: 484 490 doi:10.1093/ndt/gfl621 Advance Access publication 7 November 2006 Original Article Measurement of vascular calcification using CT fistulograms Nigel D. Toussaint
More informationCKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism
CKD-MBD in 2017 What s new? Focus on Sec Hyperparathyroidism Pieter Evenepoel Nephrology, Dialysis, and Transplantation University Hospitals Leuven April 2017, FMC Herbeumont Disclosures Research support:
More informationCoronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients
Kidney International, Vol. 65 (2004), pp. 1790 1794 Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients ALI A. HAYDAR, ADRIAN COVIC, HELEN COLHOUN, MICHAEL RUBENS,
More informationCalcium, phosphate and parathyroid metabolism in kidney transplanted patients
DOI 10.1007/s11255-009-9631-0 NEPHROLOGY - ORIGINAL PAPER Calcium, phosphate and parathyroid metabolism in kidney transplanted patients Csaba Ambrus Æ Miklos Zsolt Molnar Æ Maria Eszter Czira Æ Laszlo
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism
More informationTitle:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Author's response to reviews Title:Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism Authors: Li Fang (fangli@njmu.edu.cn)
More informationNicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD
Biomarker der kardio-renalen Achse Mannheim, 20. Januar 2017 Nicht-oxidiertes (nox-)pth: ein neuer Marker für CKD-MBD Prof. Dr. med. Thomas Bernd Dschietzig Immundiagnostik AG, Bensheim Med. Klinik m.
More informationCKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire
Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School
More information2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 01 June 2007 Product Name : Renagel Procedure No: EMEA/H/C/000254/II/56 SCIENTIFIC DISCUSSION 1/11 1. Introduction Renagel (sevelamer), a non-absorbed, calcium and metal-free
More informationMehruba Alam Ananna, Wasim Md. Mohosin Ul Haque, Muhammad Abdur Rahim, Tufayel Ahmed Chowdhury, Tabassum Samad, Md. Mostarshid Billah, Sarwar Iqbal
Original Article Correlation of serum intact parathyroid hormone and alkaline phosphatase in diabetic chronic kidney disease stage 3 to 5 patients with mineral bone disorders Mehruba Alam Ananna, Wasim
More informationParsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1
Parsabiv the control of calcimimetic delivery you ve always wanted, the sustained lowering of shpt lab values your patients deserve 1 Not an actual Parsabiv vial. The displayed vial is for illustrative
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.7, No.4, pp ,
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.7, No.4, pp 560-565, 2014-2015 Comparison of Calcium, Phosphate and Intact Parathyroid Hormone Levels Pre- and Post-Parathyroidectomy
More informationComparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):
Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,
More informationchapter 1 & 2009 KDIGO
http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3
More informationPhosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer
Hemodialysis International 2015; 19:5459 Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis sevelamer hydrochloride, calcium carbonate, and bixalomer Toru SANAI, 1
More informationParicalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients
Pediatr Nephrol (2006) 21:1434 1439 DOI 10.1007/s00467-006-0204-5 ORIGINAL ARTICLE Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients Wacharee Seeherunvong
More informationYueming Sun Æ Huihua Cai Æ Jianfeng Bai Æ Hanlin Zhao Æ Yi Miao
World J Surg (2009) 33:1674 1679 DOI 10.1007/s00268-009-0086-3 Endoscopic Total Parathyroidectomy and Partial Parathyroid Tissue Autotransplantation for Patients with Secondary Hyperparathyroidism: A New
More informationSecondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management
Secondary hyperparathyroidism in chronic kidney disease recent paradigm shift in clinical management Complete this course and earn 1 CME POINT Dr. HO Chung Ping MBBS (HK), MRCP, FRCP (Glas, Edin), FHKCP,
More informationSecondary hyperparathyroidism in dialysis patients
Secondary hyperparathyroidism in dialysis patients ( a critical approach of pharmacological treatments) Dominique JOLY Néphrologie Hôpital NECKER, Paris DFG Finn WF. J Am Soc Nephrol. 24;15:271A. Ca ++
More informationSince its inception in the 1970s, dialysis has allowed for
http://www.revistanefrologia.com 2013 Revista Nefrología. Official Publication of the Spanish Nephrology Society editorial comment See original article on page 46 Are the K/DOQI objectives for bone mineral
More informationReversal of adynamic bone disease by lowering of dialysate calcium
http://www.kidney-international.org & 26 International Society of Nephrology original article Reversal of adynamic bone disease by lowering of dialysate calcium A Haris 1, DJ Sherrard 2 and G Hercz 3 1
More informationRace Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients
J Am Soc Nephrol 11: 330 334, 2000 Race Is a Major Determinant of Secondary Hyperparathyroidism in Uremic Patients AJAY GUPTA,* LEE R. KALLENBACH, GERARD ZASUWA,* and GEORGE W. DIVINE *Division of Nephrology
More information